Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabiralizumab plus nivolumab with or without chemotherapy in advanced pancreatic cancer
2018-000339-28Phase 2Unknown
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of cabiralizumab and nivolumab in pancreatic cancer (PC) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
cabiralizumabnivolumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2018-000339-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000339-28.